Amgen Inc (AMGN)
Return on assets (ROA)
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | ||
|---|---|---|---|---|---|---|
| Net income | US$ in thousands | 6,717,000 | 6,552,000 | 5,893,000 | 7,264,000 | 7,842,000 |
| Total assets | US$ in thousands | 97,154,000 | 65,121,000 | 61,165,000 | 62,948,000 | 59,707,000 |
| ROA | 6.91% | 10.06% | 9.63% | 11.54% | 13.13% |
December 31, 2023 calculation
ROA = Net income ÷ Total assets
= $6,717,000K ÷ $97,154,000K
= 6.91%
AMGEN Inc.'s return on assets (ROA) has seen a general downward trend over the past five years. The ROA decreased from 13.13% in 2019 to 6.91% in 2023. This decline indicates that the company's ability to generate profits from its assets has weakened. Factors contributing to this trend could include changes in the company's profitability, asset efficiency, or a combination of both. Further investigation into the company's financial performance and operational efficiency may be warranted to understand the underlying reasons for the declining ROA.
Peer comparison
Dec 31, 2023
Company name
Symbol
ROA
Amgen Inc
AMGN
6.91%
Bio-Techne Corp
TECH
6.22%
Biogen Inc
BIIB
4.33%
Gilead Sciences Inc
GILD
9.12%
Halozyme Therapeutics Inc
HALO
16.25%
Krystal Biotech Inc
KRYS
1.34%
Moderna Inc
MRNA
-25.58%
Neurocrine Biosciences Inc
NBIX
7.68%
Regenxbio Inc
RGNX
-45.91%
Repligen Corporation
RGEN
1.47%
Vericel Corp Ord
VCEL
-0.90%